Wall Street brokerages expect Kadmon Holdings Inc (NYSE:KDMN) to post earnings per share (EPS) of ($0.14) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Kadmon’s earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.11). Kadmon reported earnings per share of ($0.37) in the same quarter last year, which would suggest a positive year-over-year growth rate of 62.2%. The firm is expected to issue its next earnings report on Thursday, March 5th.
On average, analysts expect that Kadmon will report full-year earnings of ($0.55) per share for the current financial year, with EPS estimates ranging from ($0.57) to ($0.51). For the next year, analysts forecast that the company will post earnings of ($0.62) per share, with EPS estimates ranging from ($0.84) to ($0.51). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Kadmon.
KDMN has been the topic of a number of recent research reports. Nomura initiated coverage on Kadmon in a report on Friday, January 10th. They issued a “buy” rating and a $10.00 target price on the stock. Cantor Fitzgerald raised their target price on Kadmon from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Zacks Investment Research raised Kadmon from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Friday, January 24th. Finally, ValuEngine raised Kadmon from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $9.84.
Kadmon stock traded down $0.11 during trading on Friday, reaching $4.52. The company had a trading volume of 899,500 shares, compared to its average volume of 1,616,890. Kadmon has a 52 week low of $1.63 and a 52 week high of $5.38. The firm’s 50-day simple moving average is $4.57 and its 200 day simple moving average is $3.51. The firm has a market capitalization of $603.71 million, a price-to-earnings ratio of -5.87 and a beta of 2.47. The company has a current ratio of 2.29, a quick ratio of 2.29 and a debt-to-equity ratio of 0.54.
In other Kadmon news, major shareholder Perceptive Advisors Llc purchased 1,470,588 shares of the business’s stock in a transaction on Monday, November 18th. The stock was acquired at an average price of $3.40 per share, for a total transaction of $4,999,999.20. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.85% of the company’s stock.
A number of hedge funds have recently modified their holdings of KDMN. Millennium Management LLC grew its position in shares of Kadmon by 67.8% during the third quarter. Millennium Management LLC now owns 5,168,469 shares of the company’s stock valued at $13,024,000 after purchasing an additional 2,087,903 shares in the last quarter. BlackRock Inc. grew its position in shares of Kadmon by 23.5% during the second quarter. BlackRock Inc. now owns 8,428,750 shares of the company’s stock valued at $17,363,000 after purchasing an additional 1,605,568 shares in the last quarter. Perceptive Advisors LLC grew its position in shares of Kadmon by 11.2% during the fourth quarter. Perceptive Advisors LLC now owns 14,636,334 shares of the company’s stock valued at $66,302,000 after purchasing an additional 1,470,588 shares in the last quarter. State Street Corp grew its position in shares of Kadmon by 51.8% during the fourth quarter. State Street Corp now owns 3,467,389 shares of the company’s stock valued at $15,707,000 after purchasing an additional 1,183,225 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Kadmon during the fourth quarter valued at about $4,295,000. Institutional investors and hedge funds own 76.74% of the company’s stock.
Kadmon Company Profile
Kadmon Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease.
Featured Story: What is the outlook for the FAANG stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.